
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Lipocine Inc (LPCN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LPCN (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $7.38
1 Year Target Price $7.38
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.78% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.47M USD | Price to earnings Ratio - | 1Y Target Price 7.38 |
Price to earnings Ratio - | 1Y Target Price 7.38 | ||
Volume (30-day avg) 2 | Beta 1.24 | 52 Weeks Range 2.68 - 6.17 | Updated Date 08/15/2025 |
52 Weeks Range 2.68 - 6.17 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.4 | Actual -0.41 |
Profitability
Profit Margin -107.11% | Operating Margin (TTM) -386.03% |
Management Effectiveness
Return on Assets (TTM) -16.76% | Return on Equity (TTM) -23.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1461780 | Price to Sales(TTM) 3.91 |
Enterprise Value -1461780 | Price to Sales(TTM) 3.91 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA 0.65 | Shares Outstanding 5419050 | Shares Floating 5261244 |
Shares Outstanding 5419050 | Shares Floating 5261244 | ||
Percent Insiders 2.91 | Percent Institutions 9.72 |
Upturn AI SWOT
Lipocine Inc
Company Overview
History and Background
Lipocine Inc. is a pharmaceutical company focused on developing innovative treatments for men's and women's health conditions utilizing its proprietary oral delivery technology. Founded in 2002, it has evolved from focusing solely on testosterone replacement therapy to exploring broader applications of its technology.
Core Business Areas
- Androgen Therapies: Focuses on developing oral testosterone replacement therapies for hypogonadism, including TLANDO.
- Women's Health: Exploring potential applications of its oral delivery technology in women's health, including pre-term birth prevention.
Leadership and Structure
Lipocine's leadership team consists of experienced pharmaceutical executives. Its organizational structure is typical of a small, publicly traded biotechnology company.
Top Products and Market Share
Key Offerings
- TLANDO: An oral testosterone replacement therapy approved for hypogonadism. Market share data is not readily available due to its relatively recent launch and evolving competitive landscape. Competitors include injectable testosterone products (e.g., Depo-Testosterone), topical gels (e.g., AndroGel), and other oral therapies (e.g., Jatenzo). Revenue data is tracked in Lipocine's financial reports.
Market Dynamics
Industry Overview
The market for testosterone replacement therapy is mature but still growing, driven by an aging population and increasing awareness of hypogonadism. The women's health market is large and diverse.
Positioning
Lipocine aims to differentiate itself through its oral delivery technology, offering patients a more convenient and potentially safer alternative to existing therapies.
Total Addressable Market (TAM)
The TAM for testosterone replacement therapy is estimated to be in the billions of dollars annually. Lipocine aims to capture a significant share of this market with TLANDO, and expand to other therapies such as pre-term birth prevention
Upturn SWOT Analysis
Strengths
- Proprietary oral delivery technology
- Approved product (TLANDO)
- Experienced management team
- Potential for pipeline expansion in women's health
Weaknesses
- Limited financial resources
- Dependence on a single approved product
- Commercialization challenges for TLANDO
- History of regulatory setbacks
Opportunities
- Expanding TLANDO market share
- Developing new formulations using its oral delivery technology
- Partnering with larger pharmaceutical companies
- Addressing unmet needs in women's health
Threats
- Competition from established testosterone therapies
- Regulatory hurdles for new product approvals
- Patent challenges
- Market acceptance of oral testosterone
Competitors and Market Share
Key Competitors
- ABBV
- ENDP
- AGRX
Competitive Landscape
Lipocine's competitive advantage lies in its oral delivery technology, but it faces competition from established players with greater resources and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to regulatory delays and commercialization challenges.
Future Projections: Future growth depends on the success of TLANDO and pipeline development. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include focusing on TLANDO commercialization and exploring new applications of its oral delivery technology.
Summary
Lipocine is a small pharmaceutical company with an approved product and a proprietary technology. It faces challenges related to commercialization, regulatory hurdles, and limited financial resources. Success depends on expanding the market share for TLANDO and developing its pipeline. The company's volatile stock price reflects the high-risk, high-reward nature of the biotechnology industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Lipocine Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lipocine Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2013-10-22 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO Dr. Mahesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.lipocine.com |
Full time employees 16 | Website https://www.lipocine.com |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.